| scholarly article | Q13442814 |
| P50 | author | Jacqueline Boultwood | Q38600810 |
| Nigel J. Saunders | Q41672598 | ||
| Charles H. Lawrie | Q55292658 | ||
| P2093 | author name string | Francesco Pezzella | |
| Stephen Taylor | |||
| James S Wainscoat | |||
| Erica Ballabio | |||
| Jianxiang Chi | |||
| Christian S R Hatton | |||
| Daniela Tramonti | |||
| Stefano Palazzo | |||
| P2860 | cites work | Oncogenes and Cancer | Q22248112 |
| Accumulation of miR-155 and BIC RNA in human B cell lymphomas | Q24556523 | ||
| Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells | Q24618984 | ||
| Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers | Q24625794 | ||
| Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma | Q24676965 | ||
| Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation | Q24679746 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| MicroRNA gene expression deregulation in human breast cancer | Q27860690 | ||
| A microRNA polycistron as a potential human oncogene | Q27860720 | ||
| Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets | Q27860792 | ||
| c-Myc-regulated microRNAs modulate E2F1 expression | Q27861046 | ||
| MicroRNA expression profiles classify human cancers | Q28032481 | ||
| Normalization of cDNA microarray data | Q28181692 | ||
| Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray | Q28204313 | ||
| Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma | Q28209540 | ||
| Reduced accumulation of specific microRNAs in colorectal neoplasia | Q28211976 | ||
| Identification of hundreds of conserved and nonconserved human microRNAs | Q28257480 | ||
| A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia | Q28279141 | ||
| Phylogenetic shadowing and computational identification of human microRNA genes | Q28302536 | ||
| MicroRNA biogenesis: coordinated cropping and dicing | Q29547496 | ||
| Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma | Q29614238 | ||
| miR-21-mediated tumor growth | Q29616149 | ||
| Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice | Q29619279 | ||
| MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb | Q29619411 | ||
| BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas | Q29622911 | ||
| Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes | Q34066202 | ||
| Diffuse large cell lymphoma | Q34368710 | ||
| The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. | Q34714155 | ||
| MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. | Q34786558 | ||
| miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely | Q35758613 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| MicroRNA-cancer connection: the beginning of a new tale | Q36555283 | ||
| MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas | Q36734930 | ||
| MicroRNAs and haematology: small molecules, big function | Q36835898 | ||
| Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state | Q36909649 | ||
| MicroRNA expression in lymphoma | Q36922250 | ||
| Downregulation of microRNAs-143 and -145 in B-cell malignancies | Q40076849 | ||
| MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma | Q40135314 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome | Q46433707 | ||
| Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas | Q49106541 | ||
| Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. | Q52565931 | ||
| MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. | Q52582850 | ||
| Aberrant expression of microRNA in polycythemia vera. | Q53474698 | ||
| MicroRNA expression in lymphocyte development and malignancy | Q57976149 | ||
| p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas | Q73851831 | ||
| Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma | Q80281110 | ||
| MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas | Q81418207 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 7 | |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 1248-1260 | |
| P577 | publication date | 2008-12-24 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma | |
| P478 | volume | 13 |
| Q36255792 | A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma |
| Q27349177 | A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia |
| Q35566861 | A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia |
| Q38099048 | Aberrant microRNA expression in multiple myeloma |
| Q53764455 | Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. |
| Q33573515 | Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis |
| Q26773179 | Bioinformatics Resources for MicroRNA Discovery |
| Q38251994 | Challenges and opportunities of microRNAs in lymphomas. |
| Q55515075 | Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. |
| Q42144840 | Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma |
| Q33839512 | Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma |
| Q24289183 | Clinical outcome prediction by microRNAs in human cancer: a systematic review |
| Q37582348 | Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia |
| Q35021337 | Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients |
| Q90455066 | Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA |
| Q41320784 | Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas |
| Q35225279 | Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas |
| Q38138170 | Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features |
| Q33688416 | Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome? |
| Q33858819 | Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling |
| Q37533750 | Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. |
| Q35909637 | Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies |
| Q28071905 | Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma |
| Q89659978 | Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma |
| Q38970577 | Epigenetics in Multiple Myeloma. |
| Q35963272 | Epstein-Barr virus oncoprotein super-enhancers control B cell growth |
| Q41788609 | Gene regulation by small RNAs |
| Q52857590 | Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides. |
| Q37706993 | Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53 |
| Q51864519 | Immunophenotype-related microRNA expression in canine chronic lymphocytic leukemia. |
| Q45286370 | Incidence, risk factors and outcome of histological transformation in follicular lymphoma |
| Q33912418 | Integrated analysis of microRNA-target interactions with clinical outcomes for cancers |
| Q38928370 | Let-7b inhibits cell proliferation, migration, and invasion through targeting Cthrc1 in gastric cancer |
| Q93079977 | Long Non-Coding RNAs Modulate Sjögren's Syndrome Associated Gene Expression and Are Involved in the Pathogenesis of the Disease |
| Q86282937 | Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL) |
| Q90430667 | MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways |
| Q42703031 | Micro-RNA Expression and Function in Lymphomas |
| Q34122330 | MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential |
| Q35061526 | MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival |
| Q38689170 | MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy |
| Q41136238 | MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase |
| Q34221217 | MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth |
| Q35553338 | MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype |
| Q34234677 | MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response |
| Q35072776 | MicroRNA profiling of primary cutaneous large B-cell lymphomas |
| Q55021517 | MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. |
| Q54333258 | MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. |
| Q85003595 | MicroRNA-Profiling in Formalin-Fixed Paraffin-Embedded Specimens |
| Q33962495 | MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q57814100 | MicroRNAs as Biomarkers of B-cell Lymphoma |
| Q58010808 | MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma |
| Q90464161 | MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index |
| Q28254647 | MicroRNAs in B-cell lymphomas: how a complex biology gets more complex |
| Q38599607 | MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential |
| Q36524472 | MicroRNAs in diffuse large B-cell lymphoma |
| Q37970680 | Molecular profiling of aggressive lymphomas |
| Q26765273 | New insights into MicroRNAs involves in drug resistance in diffuse large B cell lymphoma |
| Q41390560 | Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma |
| Q36934675 | Predicting malignancy in thyroid nodules: molecular advances |
| Q41986451 | Predictive value of microRNAs as novel biomarkers in detection of lymphoma |
| Q37833087 | Prognostication of diffuse large B-cell lymphoma in the rituximab era. |
| Q93032482 | Regulatory mechanisms of B cell responses and the implication in B cell-related diseases |
| Q48201625 | Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. |
| Q27016561 | Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) |
| Q42923456 | Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma |
| Q53089445 | Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. |
| Q54322917 | Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. |
| Q33893875 | Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. |
| Q64095238 | Single Nucleotide Polymorphisms in Contribute to Protection Against Non-Hodgkin Lymphoma (NHL) in Caucasian Populations |
| Q64245615 | Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma |
| Q37781972 | The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas |
| Q26797469 | The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential |
| Q39281793 | The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. |
| Q37815142 | The molecular background of aggressive B cell lymphomas as a basis for targeted therapy |
| Q39335736 | Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database |
| Q35166811 | Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach |
| Q26746573 | miR-155 as a Biomarker in B-Cell Malignancies |
| Q35739550 | miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients |
| Q36719087 | miR-31 and miR-17-5p levels change during transformation of follicular lymphoma |
| Q64279395 | miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy |
| Q42563520 | miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma |
| Q37770977 | miRNAs in normal and malignant B cells |
| Q50544689 | microRNAs: Key Players in Hematopoiesis. |
Search more.